Do analysts rate VIRI or UNCY?

Unicycive Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 231.22%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Unicycive Therapeutics 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is VIRI or UNCY more profitable?

Unicycive Therapeutics' return on equity of -91.50% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Unicycive Therapeutics N/A -91.50% -61.47%

Do analysts rate VIRI or VTVT?

vTv Therapeutics has a consensus price target of $55.83, indicating a potential upside of 85.37%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 vTv Therapeutics 2 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is VIRI or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% vTv Therapeutics N/A -6.27% -5.06%

Do analysts recommend VIRI or VANI?

Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 167.86%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts plainly believe Vivani Medical is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation and earnings, VIRI or VANI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Vivani Medical N/A N/A -$26.61M -$0.40 N/A

Is VIRI or VANI more profitable?

Virios Therapeutics' return on equity of -130.33% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Vivani Medical N/A -218.52% -73.92%

Do analysts rate VIRI or NRXP?

NRx Pharmaceuticals has a consensus target price of $34.50, suggesting a potential upside of 955.05%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is VIRI or NRXP more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% NRx Pharmaceuticals N/A N/A -202.92%

Do analysts rate CPIX or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Virios Therapeutics (VIRI) Competitors

$1.98 +0.06 (+2.86%)

As of 08/13/2026

Compare

VIRI vs. UNCY, VTVT, VANI, NRXP, and CPIX

Should you buy Virios Therapeutics stock or one of its competitors? Virios Therapeutics's main competitors and comparable companies include Unicycive Therapeutics (UNCY), vTv Therapeutics (VTVT), Vivani Medical (VANI), NRx Pharmaceuticals (NRXP), and Cumberland Pharmaceuticals (CPIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Virios Therapeutics compare to Unicycive Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Unicycive Therapeutics had 11 more articles in the media than Virios Therapeutics. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 0 mentions for Virios Therapeutics. Unicycive Therapeutics' average media sentiment score of 1.27 beat Virios Therapeutics' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Unicycive Therapeutics	Positive

Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Unicycive Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 231.22%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Virios Therapeutics has higher earnings, but lower revenue than Unicycive Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Unicycive Therapeutics	$680K	225.67	-$26.56M	-$2.21	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Unicycive Therapeutics' return on equity of -91.50% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Summary

Unicycive Therapeutics beats Virios Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to vTv Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Virios Therapeutics has higher earnings, but lower revenue than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
vTv Therapeutics	$36.84M	3.22	-$26.97M	-$1.06	N/A

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

vTv Therapeutics' return on equity of -6.27% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
vTv Therapeutics	N/A	-6.27%	-5.06%

In the previous week, vTv Therapeutics had 13 more articles in the media than Virios Therapeutics. MarketBeat recorded 13 mentions for vTv Therapeutics and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 beat vTv Therapeutics' score of -0.40 indicating that Virios Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
vTv Therapeutics	Neutral

vTv Therapeutics has a consensus price target of $55.83, indicating a potential upside of 85.37%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe vTv Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

vTv Therapeutics beats Virios Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Vivani Medical?

Virios Therapeutics (NASDAQ:VIRI) and Vivani Medical (NASDAQ:VANI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Vivani Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Vivani Medical shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 53.3% of Vivani Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

In the previous week, Vivani Medical had 6 more articles in the media than Virios Therapeutics. MarketBeat recorded 6 mentions for Vivani Medical and 0 mentions for Virios Therapeutics. Vivani Medical's average media sentiment score of 1.04 beat Virios Therapeutics' score of 0.00 indicating that Vivani Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Vivani Medical	Positive

Virios Therapeutics' return on equity of -130.33% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Vivani Medical	N/A	-218.52%	-73.92%

Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 167.86%. Given Vivani Medical's stronger consensus rating and higher possible upside, analysts plainly believe Vivani Medical is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Vivani Medical beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to NRx Pharmaceuticals?

Virios Therapeutics (NASDAQ:VIRI) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Virios Therapeutics has higher earnings, but lower revenue than NRx Pharmaceuticals. Virios Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
NRx Pharmaceuticals	$1.23M	96.32	-$28.62M	-$1.09	N/A

NRx Pharmaceuticals has a consensus target price of $34.50, suggesting a potential upside of 955.05%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, NRx Pharmaceuticals had 8 more articles in the media than Virios Therapeutics. MarketBeat recorded 8 mentions for NRx Pharmaceuticals and 0 mentions for Virios Therapeutics. NRx Pharmaceuticals' average media sentiment score of 0.04 beat Virios Therapeutics' score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
NRx Pharmaceuticals	Neutral

Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market.

NRx Pharmaceuticals' return on equity of 0.00% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
NRx Pharmaceuticals	N/A	N/A	-202.92%

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

NRx Pharmaceuticals beats Virios Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Cumberland Pharmaceuticals has higher revenue and earnings than Virios Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.62	-$2.84M	-$0.71	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

In the previous week, Cumberland Pharmaceuticals had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Cumberland Pharmaceuticals and 0 mentions for Virios Therapeutics. Cumberland Pharmaceuticals' average media sentiment score of 0.85 beat Virios Therapeutics' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Positive
Virios Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%
Virios Therapeutics	N/A	-130.33%	-115.00%

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cumberland Pharmaceuticals beats Virios Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIRI vs. The Competition

Export

Metric	Virios Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.13M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-7.33	775.15	269.06	25.28
Price / Sales	N/A	743.86	602.43	91.76
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	9.90	11.60	12.91	6.24
Net Income	-$5.30M	$2.77B	$3.45B	$347.60M
7 Day Performance	13.14%	0.17%	1.12%	1.07%
1 Month Performance	43.48%	0.35%	1.79%	1.03%
1 Year Performance	-58.75%	161.52%	67.69%	20.77%

Virios Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIRI Virios Therapeutics	N/A	$1.98 +2.9%	N/A	-60.3%	$38.13M	N/A	N/A	5
UNCY Unicycive Therapeutics	3.6226 of 5 stars	$5.00 -0.4%	$21.75 +335.0%	+22.4%	$137.51M	$680K	N/A	9	News Coverage Positive News Earnings Report Analyst Forecast Analyst Revision
VTVT vTv Therapeutics	2.815 of 5 stars	$33.04 -3.6%	$55.83 +69.0%	+115.7%	$135.07M	$36.84M	N/A	9	Analyst Downgrade
VANI Vivani Medical	3.827 of 5 stars	$1.39 -1.4%	$3.75 +169.8%	+6.3%	$121.59M	N/A	N/A	20	News Coverage Positive News Earnings Report
NRXP NRx Pharmaceuticals	2.3185 of 5 stars	$3.40 +1.5%	$34.50 +914.7%	+32.0%	$121.37M	$1.23M	N/A	2	News Coverage Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Competitors

VIRI vs. UNCY, VTVT, VANI, NRXP, and CPIX

How does Virios Therapeutics compare to Unicycive Therapeutics?

Summary

How does Virios Therapeutics compare to vTv Therapeutics?

Summary

How does Virios Therapeutics compare to Vivani Medical?

Summary

How does Virios Therapeutics compare to NRx Pharmaceuticals?

Summary

How does Virios Therapeutics compare to Cumberland Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Competitors

VIRI vs. UNCY, VTVT, VANI, NRXP, and CPIX

How does Virios Therapeutics compare to Unicycive Therapeutics?

Does the media refer more to VIRI or UNCY?

Which has more risk and volatility, VIRI or UNCY?

Do analysts rate VIRI or UNCY?

Which has preferable valuation & earnings, VIRI or UNCY?

Do insiders & institutionals hold more shares of VIRI or UNCY?

Is VIRI or UNCY more profitable?

Summary

How does Virios Therapeutics compare to vTv Therapeutics?

Which has preferable valuation and earnings, VIRI or VTVT?

Do institutionals and insiders have more ownership in VIRI or VTVT?

Is VIRI or VTVT more profitable?

Does the media refer more to VIRI or VTVT?

Do analysts rate VIRI or VTVT?

Which has more volatility and risk, VIRI or VTVT?

Summary

How does Virios Therapeutics compare to Vivani Medical?

Which has higher valuation and earnings, VIRI or VANI?

Do institutionals & insiders believe in VIRI or VANI?

Which has more volatility & risk, VIRI or VANI?

Does the media refer more to VIRI or VANI?

Is VIRI or VANI more profitable?

Do analysts recommend VIRI or VANI?

Summary

How does Virios Therapeutics compare to NRx Pharmaceuticals?

Which has stronger valuation and earnings, VIRI or NRXP?

Do analysts rate VIRI or NRXP?

Does the media refer more to VIRI or NRXP?

Which has more risk and volatility, VIRI or NRXP?

Is VIRI or NRXP more profitable?

Do insiders and institutionals believe in VIRI or NRXP?

Summary

How does Virios Therapeutics compare to Cumberland Pharmaceuticals?

Which has stronger valuation & earnings, CPIX or VIRI?

Which has more volatility & risk, CPIX or VIRI?

Does the media favor CPIX or VIRI?

Do analysts rate CPIX or VIRI?

Is CPIX or VIRI more profitable?

Do insiders and institutionals hold more shares of CPIX or VIRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools